Ivabradine Zentiva

Ivabradine, the active ingredient in Ivabradine Zentiva, is a If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina pectoris and chronic heart failure in adults with reduced ejection fraction, helping to lower heart rate without affecting contractility.

GNH USA supplies Ivabradine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides quality‑assured batches under strict regulatory oversight to meet the needs of healthcare providers in multiple regions.

Ivabradine is used to manage conditions related to cardiac ischemia and heart failure by reducing heart rate.

Chronic stable angina pectoris: reduces frequency of angina episodes and improves exercise tolerance. Chronic heart failure (NYHA class II–III) with reduced ejection fraction: lowers heart rate, alleviates symptoms and may decrease hospital admissions. Heart‑failure patients on maximally tolerated beta‑blockers: provides additional heart‑rate reduction when beta‑blocker dose cannot be increased.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Bradycardia: symptomatic slowing of heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: often related to reduced heart rate.

Serious or Rare Side Effects: - Atrial fibrillation: irregular rapid heart rhythm. - Severe bradycardia leading to syncope. - Retinal visual loss: rare but potentially permanent. - High‑grade atrioventricular block.

When prescribing ivabradine, several safety considerations should be observed.

Heart rate monitoring: check baseline and periodic heart rate to avoid excessive bradycardia. Concomitant beta‑blockers: use with caution, may cause profound bradycardia. Severe hepatic impairment: dose adjustment may be required. Pregnancy and lactation: safety not established; avoid unless clearly needed. Patients with sick sinus syndrome or atrioventricular block: contraindicated. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Ivabradine interacts with several medicines that affect its metabolism or heart‑rate effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels, risk of bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce efficacy. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin) without monitoring: risk of severe bradycardia.

Moderate Interactions (Monitor Closely):\n- Verapamil and diltiazem: moderate CYP3A4 inhibition, may raise ivabradine concentrations. - CYP3A4‑modulating antidepressants (e.g., fluoxetine): modestly increase levels. - Electrolyte disturbances such as hypokalemia: may predispose to arrhythmias.